Table 2.
Correlation Between Fluoroquinolone Use and Emergence of Fluoroquinolone Resistance Among Gram-Negative Bacilli Recovered From Hospitalized Pediatric Patients, Alfred I. duPont Hospital for Children, 2001–2009
| Fluoroquinolone Use* | Ciprofloxacin Use* | Levofloxacin Use* | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
||||||||||||
| DA/1000 PD/Y | DoT/1000 PD/Y | DA/1000 PD/Y | DoT/1000 PD/Y | DA/1000 PD/Y | DoT/1000 PD/Y | ||||||||||
|
|
|
|
|
|
|
||||||||||
| Coefficient (r)† | P | Coefficient (r)† | P | Coefficient (r)† | P | Coefficient (r)† | P | Coefficient (r)† | P | Coefficient (r)† | P | ||||
| Ciprofloxacin resistance | 0.879 | 0.001 | 0.938 | 0.001 | 0.846 | 0.001 | 0.937 | 0.001 | 0.930 | 0.001 | 0.951 | 0.001 | |||
| Levofloxacin resistance | 0.874 | 0.001 | 0.945 | 0.001 | 0.811 | 0.001 | 0.941 | 0.001 | 0.928 | 0.001 | 0.969 | 0.001 | |||
*
Expressed as doses administered per 1000 patient-days per year (DA/1000 PD/Y) and days of therapy per 1000 patient-days per year (DoT/1000 PD/Y).
†
Pearson correlation coefficient.